Ocugen (OCGN) Projected to Post Earnings on Wednesday

Ocugen (NASDAQ:OCGN) is expected to post its quarterly earnings results before the market opens on Wednesday, March 5th. Analysts expect Ocugen to post earnings of ($0.05) per share and revenue of $0.30 million for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Ocugen Stock Performance

OCGN opened at $0.61 on Tuesday. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.04. The company’s fifty day moving average price is $0.74 and its two-hundred day moving average price is $0.92. Ocugen has a 1-year low of $0.60 and a 1-year high of $2.11. The company has a market cap of $176.28 million, a price-to-earnings ratio of -3.36 and a beta of 3.82.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Chardan Capital restated a “buy” rating and set a $6.00 price objective on shares of Ocugen in a report on Thursday, February 13th. HC Wainwright upped their price objective on shares of Ocugen from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Thursday, February 13th.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients’ health. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.